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Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to cause fetal renal
damage in pregnancy. Due to conﬂicting reports in the literature, their safety after ﬁrst trimester exposure has been debated. Our
aim was to determine whether the use of ACE inhibitors or ARBs in the ﬁrst trimester of pregnancy is associated with an increased
risk for major malformations or other adverse outcomes. All subjects were prospectively enrolled from among women contacting
a teratogen information service. At initial contact, details of maternal medical history and exposures were collected and follow-
up interviews were conducted to ascertain pregnancy outcomes. Two comparator groups, women with hypertension treated with
other antihypertensives, and healthy controls were also recruited. Baseline maternal characteristics were not diﬀerent among the
three groups. There were no diﬀerences in rates of major malformations. Both the ACE-ARBs and disease-matched groups exhib-
itedsigniﬁcantlylowerbirthweightandgestationalagesthanthehealthycontrols(P<0.001forbothvariables).Therewasasigni-
ﬁcantly higher rate of miscarriage noted in the ACE/ARB group (P<0.001). These results suggest that ACE inhibitors/ARBs are
not major human teratogens; however, they may be associated with an increased risk for miscarriage.
1.Background
Hypertension is a fairly common condition, estimated to
aﬀect between 6% and 8% of pregnancies [1]. It can
occur as one of four conditions: chronic hypertension, pre-
eclampsia-eclampsia, chronic hypertension with superimpo-
sed preeclampsia, and gestational hypertension [2]. Hyper-
tension is associated with an increased risk of adverse eﬀects
inboththemotherandthefetus,andtreatmentiswarranted.
Perinatal and infant complications may include prematu-
rity, neonatal death, placental abruptions, and small-for-
gestational age babies [3–7]. Maternal complications include
pulmonary edema, hypertensive encephalopathy, retinopa-
thy, cerebral hemorrhage, and acute renal failure [2], which
are worse in untreated patients.
Data on the safety of antihypertensive drugs in preg-
nancy are relatively sparse [8]. Based on the existing data,
methyldopa, nifedipine, labetolol, and other beta-blockers
have been considered the drugs of choice in the treatment
of hypertensive disorders in pregnancy [9].
Angiotensin converting enzyme inhibitors (ACE) are
now widely used as ﬁrst-line medications in nonpregnant
hypertensive patients. A more recent class of agents, the
angiotensin II receptor blockers (ARBs) are also gaining in
popularity. Unfortunately, both of these classes of drugs have
been contraindicated in pregnancy because of their associa-
tion with characteristic adverse fetal eﬀects [9] when used
beyond the ﬁrst trimester of pregnancy, including fetal hypo-
calvaria and renal insuﬃciency. The etiology of these defects
appears to be related to fetal hypotension and reduced renal
blood ﬂow in the fetus.
Intrauterine growth restriction, prematurity, patent duc-
tus arteriosus, severe neonatal hypotension, neonatal anuria,
and neonatal or fetal death have also been observed with
these drugs [10]. Anuria associated with oligohydramnios
may produce fetal limb contractures, craniofacial defor-
mities, and pulmonary hypoplasia. Based on their similar
pharmacologic eﬀects, it is generally assumed that the ARBs
will behave in much the same manner although published2 Obstetrics and Gynecology International
data on large numbers of exposed pregnancies do not exist
[11–19]. To date, most human cohort studies or case series
have failed to ﬁnd teratogenic eﬀects of ACE inhibitors after
ﬁrst trimester exposure [11, 20–24]. Recently, based on a
relatively small cohort study, Cooper et al. suggested an in-
creased risk of cardiovascular eﬀects with ﬁrst trimester use
of these agents [25]. These ﬁndings, if real, are of major
concern, because ACE and ARBs continue to be used in
women of reproductive age, many of whom may use inad-
equate contraception [26, 27]. Moreover, since half of all
pregnancies are unplanned [28, 29], inadvertent exposures
to ACE and ARBs in pregnancy will continue to occur.
The primary objective of this study was to determine the
risk for major congenital malformations following maternal
exposure to ACE inhibitors and ARBs during the ﬁrst tri-
mester of pregnancy.
2. Methods
This was a prospective, observational, controlled cohort
study. Eligible women were identiﬁed among callers to the
Motherisk Program at the Hospital for Sick Children in
Toronto. The Motherisk Program is a counseling service for
women, their families, and health professionals on the safety
or risk of drugs, chemicals, radiation, and infection during
pregnancy. The study groups consisted of women who con-
tacted the Motherisk Program concerning exposure to ACE-
ARBs during the ﬁrst trimester, other antihypertensives in
pregnancy and healthy comparators not exposed to any
known teratogen or medications for chronic conditions. Any
patient reporting use of ACE/ARBs into pregnancy was eli-
gible for inclusion. We controlled for potential eﬀects of
hypertension by comparing this group to two other groups
of subjects, women exposed to other antihypertensive agents
(including methyldopa or calcium channel blockers), and a
healthygroupwithouthypertension.Thecomparatorgroups
were matched to the study groups by gestational age at
recruitment, maternal age, and alcohol and cigarette use.
The healthy comparator group was also selected from among
callers to the Motherisk program. These women had no
chronic medical conditions. Subjects were excluded if they
were unwilling or unable to complete the follow-up inter-
views in English.
At initial contact with the patient before or during the
early weeks of pregnancy, standardized questionnaires were
used to document maternal medical history and exposures.
Information about current and past pregnancies was ob-
tained as was details about concurrent medical conditions.
After the expected date of delivery, patients were followed
up; the information collected at intake was complimented
with additional details on medical conditions or exposures
occurring since the initial contact. Details about delivery and
infant outcomes were also recorded at follow-up.
T h ep r i m a r yo u t c o m em e a s u r ew a st h er a t e so fm a j o r
malformations, which was compared among the 3 groups.
Secondary endpoints included live birth rates, birth weight,
gestational age, rates of perinatal, and neonatal complica-
tions as well as rates of miscarriage. Possible confounding
factors,such as the presence of diabetes, were alsoconsidered
in the analysis.
The rates of major malformations among the 3 groups
were compared using the chi-square test or Fisher’s exact test
as appropriate. Continuous data were compared using the
Kruskal-Wallis analysis of variance for three group compari-
sons.Analphalevelof0.05wasconsideredstatisticallysignif-
icantandtwo-tailedtestswereusedforallanalyses.Statistical
analysis was performed with SigmaStat software (version
3.0).
This study was approved by the Research Ethics Board of
the Hospital for Sick Children.
3. Results
We were able to successfully collect and follow 138 preg-
nancies exposed to ACE inhibitors or ARB’s, 112 pregnan-
cies exposed to “other” antihypertensives and 138 healthy
pregnancies.Therewerenosigniﬁcantdiﬀerencesamongthe
three groups in terms of maternal characteristics (Table 1),
as the ACE/ARB group was matched with the healthy com-
parator group on most of these parameters. In the ACE/ARB
group, the majority of women were exposed to these drugs
exclusively in the ﬁrst trimester (114 women—90%). A total
of 8 (6.3%) women were exposed to these drugs in the ﬁrst
and second trimester, while only 6 (4.7%) continued the
drugs for all three trimesters. The ACE/ARB group included
38 (27.5%) women exposed to ramipril, 25 (18.1%) exposed
to lisinopril, and 15 (10.9%) women exposed to enalapril
(Table 2). In the ACE/ARB group, there were 18 diabetics
(13%), 6 with Type 1 diabetes mellitus and 12 with Type II
diabetes mellitus.
When comparing pregnancy outcomes (Table 3), there
werenodiﬀerencesinsexofoﬀspringorratesoffetaldistress.
There were signiﬁcant diﬀerences in birth weight and gesta-
tional age at delivery with both the hypertensive patient
groups exhibiting lower birth weights (3225g ACE/ARB
group, 3063g other antihypertensives, and 3511g healthy
controls, P<0.001) and earlier gestational ages at delivery
(37.6 weeks ACE/ARB group, 37.8 weeksother antihyperten-
sives, and 39.6 weeks healthy controls, P<0.001) compared
to the healthy controls. There was a signiﬁcantly higher rate
of miscarriages in the ACE/ARB group, as compared to the
“other” antihypertensive and healthy control groups (18.0%,
8.9%, and 11.8%, resp., P<0.001).
There were 2 cases of major malformations in each of
the three groups (Table 2), with no statistical diﬀerences
among them (P = 0.99). As there was not a higher rate of
malformations in the exposed group, we did not perform
detailed analysis with diabetes as a covariate; however, one
malformed case in the treatment group was from a diabetic
mother. In addition, among the ACE/ARB group two of
the spontaneous abortions occurred in diabetic mothers.
Analyzing the pregnancy outcomes excluding these two cases
did not change the signiﬁcance in the rate of spontaneous
abortions.Obstetrics and Gynecology International 3
Table 1: Characteristics of included subjects.
Characteristic ACE/ARB exposed
(n = 138)
Other antihypertensives
(n = 110)
Healthy nonexposed
(n = 138) P value
Age (yrs ±SD)∗ 34.9 ±4.93 4 .3 ±4.23 3 .9 ±4.50 . 1 8
Gravidity (%)†
1
2
≥3
41 (29.7)
39 (28.3)
58 (42.0)
31 (28.2)
41 (37.3)
38 (34.5)
41 (29.7)
41 (29.7)
56 (40.6)
0.60
Parity (%)†
0
1
≥2
59 (42.7)
38 (27.5)
41 (29.7)
44 (40.0)
46 (41.8)
20 (18.2)
57 (41.3)
47 (34.1)
34 (24.6)
0.13
Previous miscarriage (%)†
0
1
≥2
110 (79.7)
17 (12.3)
11 (8.0)
81 (73.6)
22 (20.0)
7 (6.4)
105 (76.1)
21 (15.2)
12 (8.7)
0.54
Previous elective abortions (%)†
0
≥1
119 (86.2)
19 (13.8)
103 (93.6)
7 (6.4)
123 (89.1)
15 (10.9) 0.27
Gestational age at call (wks ±SD)‡ 7.0 ±3.41 0 .5 ±8.37 .4 ±3.40 . 0 9
Alcohol†
No
Light
114 (85.1)
20 (14.9)
100 (90.1)
11 (9.9)
125 (90.6)
13 (9.4) 0.30
Smoking†
No
Yes
117 (88.0)
16 (12.0)
102 (93.6)
7 (6.4)
129 (93.5)
9 (6.5) 0.18
∗One-way Anova, †chi-square test, ‡one-way Anova on ranks.
Table 2: Speciﬁc ACE/ARB’s used by expose subjects.
Count (%)
Ramipril 38 (27.5%)
Lisinopril 25 (18.1%)
Enalapril 15 (10.9%)
Monopril 8 (5.8%)
Valsartan 8 (5.8%)
Perindopril 7 (5.1%)
Candesartan 6 (4.3%)
Irbesartan 6 (4.3%)
Losartan 5 (3.6%)
Quinapril 5 (3.6%)
Cilazapril 3 (2.2%)
Fosinopril 3 (2.2%)
Telmisartan 3 (2.2%)
Captopril 2 (1.4%)
Prinivil 1 (0.7%)
Trandolapril 1 (0.7%)
Polytherapy 2 (1.4%)
4. Discussion
Establishing the safety of ACE inhibitors and ARBs after ﬁrst
trimester exposure is important for a number of reasons.
Most notably is that women continue to need eﬀective treat-
ment for their existing chronic hypertension and that a large
numberofpregnancieswillbeexposedinadvertentlytothese
agents. Accurate information on the safety of these agents
will assist women and their health care practitioners in
making rational choices about appropriate treatment. While
there is a consensus that ACE inhibitor/ARBs should be
discontinued when pregnancy is diagnosed to prevent fetal
renal damage and associated complications, women often do
not plan pregnancy, and fetal exposure in the ﬁrst trimester
is inevitable.
Our results are reassuring and consistent with a growing
body of evidence that did not ﬁnd an apparent increased
risk for malformations among liveborns following exposure
to ACE inhibitor/ARBs in early pregnancy [11]. In fact, the
rates of malformations were comparable to our healthy com-
parator group. Given that the ACE/ARBs are known to aﬀect
the fetal renin-angiotensin axis which becomes active in the
secondtrimester,itisnotsurprisingthattodate,adversefetal
eﬀects of these agents have been shown only after exposures
which continued into the second half of pregnancy. Our
ﬁndings support the current hypothesis that teratogenic
eﬀects are likely mediated through disruptions in the renin-
angiotensin axis and, therefore, not observed with such early
exposures.
There were signiﬁcantly more spontaneous abortions in
the ACE/ARB group as compared to the other antihyperten-
siveorhealthygroups.Someanimaldatasupportthisﬁnding4 Obstetrics and Gynecology International
Table 3: Pregnancy outcomes following exposure to ACE/ARBs or other antihypertensives as compared to a healthy comparator group.
Characteristic ACE/ARB exposed
(n = 139a)
Other antihypertensives
(n = 112b)
Healthy nonexposed
(n = 138) P value
Fetal outcome
Livebirth
Spontaneous abortion
Elective abortion
Fetal death
108 (77.7%)
25 (18.0%)
6 (4.3%)
0
105 (93.7%)
4 (8.9%)
0
3 (2.7%)
120 (88.2%)
16 (11.8%)
0
0
<0.001
Gestational age at birth (wks ±SD) 37.6 ±3.13 7 .8 ±2.83 9 .6 ±1.6 <0.001
Delivery
Vaginal
Cesarean section
62/108 (57.4%)
46/108 (42.6%)
57/106 (53.8%)
49/106 (46.2%)
83/120 (69.1%)
37/120 (30.8%) 0.045
Preterm delivery
No
Yes
81/108 (75%)
27/108 (25%)
79/105 (75.2%)
26/105 (24.8%)
117/120 (97.5%)
3/120 (2.5%) <0.001
Birth weight (grams ±SD) 3225 ±862 3063 ±839 3511 ±471 <0.001
Sex
Male 59 (54.6%) 49 (46.6%) 57 (47.5%) 0.43
Fetal malformations†
Yes 2/108 (1.8%) 2/105 (1.9%) 2/120 (1.6%) 0.99
aIncluding 1 twin pregnancy.
bIncluding 2 twin pregnancies.
†Fetal malformations are reported as a proportion of liveborn (in the ACE/ARB group-1 choanal atresia and 1 hypospadias, in the other antihypertensives
group-1 unspeciﬁed heart murmur and 1 undescended testicle, in the health unexposed group-1 Down’s syndrome and 1 inguinal hernia).
showing an increase in mortality among fetuses exposed
during organogenesis [30]. This may also be the result of
confounding eﬀects of underlying maternal conditions, in-
cluding higher incidence of diabetes mellitus among women
receiving ACE/ARBs [31], but the possibility of spontaneous
abortions as a result of fetal malformation cannot be ex-
cluded.Inaddition,whilethenumberofdiabeticswithspon-
taneous abortion was small, precluding our ability to per-
form a regression analysis, excluding these two cases for a
subgroup analysis did not change the signiﬁcant ﬁndings of
the spontaneous abortion outcome.
In the three-way comparison, there was a signiﬁcant dif-
ference in mean gestational age at birth as well as birth
weight, with babies born either to mothers exposed ACE/
ARBs or to other antihypertensive drugs exhibiting a lower
meangestationalagesatbirthaswellasalowerbirthweights.
Thedecreaseingestationalageatbirthaswellasbirthweight
is consistent with the ﬁndings in women with chronic hyper-
tension [32], attributable to placental dysfunction and de-
creased placental blood ﬂow [30]. Including a disease-mat-
ched comparison group, our data suggest that the decrease
in gestational age at birth and the lower birth weight are
likely related to disease eﬀects similar to all previous studies.
Our ability to detect small increases in the risk of major
malformations is limited by the available sample size.
Though this cohort has an 80% power (with α = 0.05) to
detect only a 2.5-fold increased risk, however, our data are
in agreement with several recent published cohort studies
and series [11, 20–24, 33], which failed to show increased
malformation rates after ﬁrst trimester exposure to ACE
inhibitors/ARBs. In addition, we were unable to provide
analysis on any particular ACE/ARB, to determine if there
are diﬀerential eﬀects of the two classes of drugs, or to assess
for dose eﬀects as the numbers in any particular drug-dose
combination were small.
Our study may be limited by population selection bias.
Namely, subjects were recruited following contact with a
teratogeninformationserviceandmaynotrepresentthegen-
eral antihypertensive using population. These are patients
whohavesoughtoutadditionalinformationabouttheirrisks
may be more diligent about seeking out prenatal or medical
care in general.
The positive study by Cooper et al. [25] has been heav-
ily criticized for inappropriately addressing potential con-
founders such as diabetes [31], some of which may not have
been diagnosed. A large study by Malm et al. suggest that
the apparent increased risk of ACE inhibitor is the result
of maternal diabetes, as exposure to ACE inhibitors without
diabetes was not associated with a higher teratogenic risk
[33]. While we had insuﬃcient cases to rule out a possible
confounding eﬀect of diabetes in our cohort, we had a sub-
stantial proportion of subjects with underlying diabetes, and
it is apparent that subjects on ACE/ARBs are more likely to
be diabetics than those on other antihypertensives.
Our ﬁndings suggest that inadvertent exposure to ACE
inhibitors/ARBs in the ﬁrst trimester of pregnancy may not
present signiﬁcant risks for malformations in live births but
maybeassociatedwithhigherratesofspontaneousabortion.
However,giventhestrongevidenceforteratogenicitybeyond
the ﬁrst trimester and the availability of other safer eﬀective
antihypertensives in pregnancy, it is imperative that women
on such agents receive prompt attention in the early part of
pregnancy so that their antihypertensive medications can be
appropriately adjusted.Obstetrics and Gynecology International 5
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